1.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000499633, NCCTG-N0574, ACOSOG-N0574, N0574, NCT00377156
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA184-156, 2011-000850-48, NCT01450761
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: SCLC, NCT01487499
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 79 Sponsor: Other Protocol IDs: F080929010, UAB 0818, NCT00856830
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02533, MDA-2009-0582, U01CA062461, N01CM62202, CDR0000686136, 2009-0582, 8543, NCT01217411
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Immunogen 0007, NCT01237678
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01985, E2511, ECOG-E2511, CDR0000736704, U10CA021115, NCT01642251
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14631, I4J-MC-HHBE, 2012-003174-83, NCT01722292
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
11.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-15206, MCC-IRB-9792, MCC 15206, INTROGEN-RAC-0705-857, NCT00618891
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LUN06-113, NCT00613626
|
|
13.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000659547, NCCTG-N0923, N0923, NCT01017601
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-08-026, NCT01051037
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 78,256, NCT01237457
|
|
17.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000690182, RTOG-1012, NCT01262560
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12-1726, NCI-2013-00402, NCT01803269
|
|
19.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: NHLBI Protocol IDs: 080186, 08-H-0186, NCT00720785
|
|
20.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 24486-HERCREEM, HERCREEM, NCT00889954
|
|
21.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C4-08-001, NCT00891280
|
|
22.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0555, NCT00895128
|
|
23.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090173, 09-C-0173, NCT00926640
|
|
24.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110041, 11-C-0041, NCT01258868
|
|
25.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02500, UPCI 10-115, CDR0000700997, U01CA069856, U01CA099168, U01CA062502, U01CA070095, U01CA062505, 8808, NCT01366144
|